Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2022 | How MRD assessment can inform treatment decisions in AML

Thomas Cluzeau • 12 Jun 2022
EHA 2022
Acute Myeloid Leukemia Leukemia Cytarabine Daunorubicin

Thomas Cluzeau, MD, PhD, Central University Hospital of Nice, Nice, France, shares some insights into how measurable residual disease (MRD) assessment can inform treatment decisions in acute myeloid leukemia (AML), highlighting the importance of MRD as a predictive marker for long-term survival and as a method of evaluating the efficiency of therapeutic agents. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

More from Thomas Cluzeau

1:40
Highlights in LR-MDS at the ASH 2023 meeting
Thomas Cluzeau • 9 Dec 2023
1:55
Long-term real-world experience of CPX-351 in patients with t-AML and MRC-AML
Thomas Cluzeau • 9 Dec 2023
2:17
VENTOGRAFT trial: AZA, VEN, and DLI in patients with MDS and AML who have relapsed following alloSCT
Thomas Cluzeau • 10 Dec 2023
Novel targets, combinations & treatments
Eunice Wang et al. • 4 Sep 2023

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals